成纤维生长因子23与慢性肾病不良预后的关系及治疗策略

成纤维生长因子23(fibroblast growth factor 23，FGF23)是由骨分泌的一种激素，不仅参与慢性肾病(chronic kidney disease，CKD)的病理生理过程，而且与其不良预后密切相关。在CKD早期，血清FGF23水平即出现升高，而逐 渐升高的FGF23可通过不同机制引起CKD患者心肌病变、炎症、血管钙化以及低维生素D水平等，与CKD进展、心血 管并发症甚至死亡有关。目前降低FGF23的手段包括减少磷的摄入与吸收、补充FGF23抗体、使用拟钙剂及肾移植等。

Correlation of fibroblast growth factor 23 with adverse prognosis of chronic kidney disease and therapy strategy

Fibroblast growth factor 23 (FGF23) is a hormone secreted by the bone. It is not only involved in the pathophysiological process of chronic kidney disease (CKD), but also associated with the poor prognosis. In patients with CKD, serum FGF23 levels are elevated in early phase. The increased FGF23 levels gradually lead to myocardial hypertrophy, infl ammatory, vascular calcifi cation, and low level of vitamin D, which contribute to the progress of CKD, cardiovascular complications and even death. Presently, there are several ways to reduce FGF23 levels, including decrease of intake and block of phosphorus absorption, supplement of FGF23 antibody and pseudo calcium or renal transplantation